WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H555448
CAS#: 2089293-61-6
Description: NAcM-OPT is a specific, reversible small molecule inhibitor targeting N-Acetyl-UBE2M interaction with DCN1 with IC50 of 79 nM
Hodoodo Cat#: H555448
Name: NAcM-OPT
CAS#: 2089293-61-6
Chemical Formula: C23H29Cl2N3O
Exact Mass: 433.17
Molecular Weight: 434.405
Elemental Analysis: C, 63.59; H, 6.73; Cl, 16.32; N, 9.67; O, 3.68
Synonym: NAcM-OPT; NAcM OPT; NAcMOPT;
IUPAC/Chemical Name: 1-benzyl-1-(1-butylpiperidin-4-yl)-3-(3,4-dichlorophenyl)urea
InChi Key: VPHJABWIKCBGMC-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H29Cl2N3O/c1-2-3-13-27-14-11-20(12-15-27)28(17-18-7-5-4-6-8-18)23(29)26-19-9-10-21(24)22(25)16-19/h4-10,16,20H,2-3,11-15,17H2,1H3,(H,26,29)
SMILES Code: O=C(NC1=CC=C(Cl)C(Cl)=C1)N(CC2=CC=CC=C2)C3CCN(CCCC)CC3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 434.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Scott DC, Hammill JT, Min J, Rhee DY, Connelly M, Sviderskiy VO, Bhasin D,
Chen Y, Ong SS, Chai SC, Goktug AN, Huang G, Monda JK, Low J, Kim HS, Paulo JA,
Cannon JR, Shelat AA, Chen T, Kelsall IR, Alpi AF, Pagala V, Wang X, Peng J,
Singh B, Harper JW, Schulman BA, Guy RK. Blocking an N-terminal
acetylation-dependent protein interaction inhibits an E3 ligase. Nat Chem Biol.
2017 Aug;13(8):850-857. doi: 10.1038/nchembio.2386. Epub 2017 Jun 5. PubMed PMID:
28581483; PubMed Central PMCID: PMC5577376.